Name | Type | Posted | Actions |
|---|---|---|---|
https://health.mil/PandT | LINK | Jun 8, 2026 | |
DoD Formulary Placement of FDA Newly Approved Drugs.pdf | Jun 8, 2026 | ||
Price Appendix FAQ NAD.pdf | Jun 8, 2026 | ||
Price List - Zolymbus - Glaucoma Agents - Prostaglandin.xlsx | XLSX | Jun 8, 2026 | |
Price List - Nereus - Antiemetic-Antivertigo Agents - NA.xlsx | XLSX | Jun 8, 2026 | |
Price List - Idvynso - Antiretrovirals - Combinations.xlsx | XLSX | Jun 8, 2026 | |
Price List - Bysanti - Antipsychotic Agents - Atypical.xlsx | XLSX | Jun 8, 2026 | |
RFQ HT9402-26-Q-9303 NAD.pdf | Jun 8, 2026 |
Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Contact and place of performance
Julia Trang
TX 78230
USA
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effec...
View morea. Bysanti - Antipsychotic Agents - Atypical
b. Idvynso - Antiretrovirals - Combinations
c. Nereus - Antiemetic-Antivertigo Agents – N/A
d. Zolymbus - Glaucoma Agents - Prostaglandin
The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9303.
Pre-quotation teleconference is on June 10, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POCs in Part 2.3.1., no later than the date stated in Part 2.3.2.
The Defense Health Agency Aurora, on behalf of the Tricare Management Activity, issued solicitation HT9402-26-Q-9303 to establish an integrated pharmacy benefits program for the Military Health System. Pursuant to 10 U.S.C. § 1074g and 32 CFR Section 199.21, the Department of War Pharmacy and Therapeutics Committee evaluates the clinical and cost effectiveness of pharmaceutical agents to determine their status on the Uniform Formulary. This process includes classifying agents as generic, formulary, Basic Core Formulary, Extended Core Formulary, or non-formulary. The agency intends to award Uniform Formulary Blanket Purchase Agreements and Uniform Formulary Additional Discount Program Agreements based on Committee decisions regarding specific drug classes.
This solicitation specifically addresses the review of newly approved drugs scheduled for the August 2026 Committee meeting, including Bysanti, Idvynso, Nereus, and Zolymbus. The procurement falls under NAICS 325412 Pharmaceutical Preparation Manufacturing and PSC 6505 Drugs and Biologicals. Performance is located in Texas, and there is no set-aside designated for this requirement. Supporting documentation includes eight attachments such as price lists, frequently asked questions, and official policy documents regarding the placement of FDA-approved drugs.
Responses to this solicitation are due by June 29, 2026. A pre-quotation teleconference is scheduled for June 10, 2026, with participation details provided in the solicitation instructions. Clinical question responses must be submitted via email to the designated point of contact, Julia Trang. The Request for Quotation includes specific appendices for the Blanket Purchase Agreement and Additional Discount Program, as well as instructions for submitting quotes for pharmaceutical agents within the identified drug classes.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.